Management of rheumatoid arthritis: summary of NICE guidance. - Wikidata - awgldk - TriplyDB

Management of rheumatoid arthritis: summary of NICE guidance.

Management of rheumatoid arthritis: summary of NICE guidance.

http://www.wikidata.org/entity/Q35699212

about

The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.Strengthening and stretching for rheumatoid arthritis of the hand (SARAH): design of a randomised controlled trial of a hand and upper limb exercise intervention--ISRCTN89936343.Illness perceptions in patients receiving rheumatology rehabilitation: association with health and outcomes at 12 months.Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.Successful use of mRNA-nucleofection for overexpression of interleukin-10 in murine monocytes/macrophages for anti-inflammatory therapy in a murine model of autoimmune myocarditis.Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage.Adverse outcomes following hand surgery in patients with rheumatoid arthritis Certolizumab in the long-term treatment of rheumatoid arthritis.ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.Biologics-based therapy for the treatment of rheumatoid arthritis.Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review.The optimal combination therapy for the treatment of early rheumatoid arthritis.Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.Hand exercises for patients with rheumatoid arthritis: an extended follow-up of the SARAH randomised controlled trial.What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?The Sheffield rheumatoid arthritis health economic model.Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial.Delayed addition of glucocorticoids selectively suppresses cytokine production in stimulated human whole blood.Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis.Clinical effectiveness of biologics in clinical practice.Guidelines for the drug treatment of rheumatoid arthritis.Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients.Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada.Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial.Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.The immunosuppressive drug azathioprine inhibits biosynthesis of the bacterial signal molecule cyclic-di-GMP by interfering with intracellular nucleotide pool availability.Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007.

P2860

Q24564701-12C1BFA5-F578-459A-ABD7-7227E15ACB26 Q30240229-64D44D36-2C72-4666-959D-A35812051199 Q34047753-9976118D-262B-4D91-85E9-10E9E50F3F7D Q34354935-8C0B78E7-F316-41D5-BBAD-CF93BB828811 Q34486680-2FED77D1-214D-4125-8407-9727478AA1C7 Q34550060-FDF20D85-1FDC-41A3-B0B9-A5CBA3F4653B Q34769962-03A5C7A2-93E2-4784-B9EF-35AE7377347F Q35236926-B2ECDD69-83BE-4D68-A56D-C39ED9C1D0A4 Q35577166-4029B82D-E3BF-43F2-98FF-6AAF2D92EE5D Q36098311-5E6E0702-9D43-4419-B752-B2F95C4BF470 Q36519827-FD9912CD-D1A7-4D74-B9C2-B89EE120DD90 Q36882850-17EE43B5-4F61-417A-8C56-26576FD25932 Q37088376-E695B0EF-015B-4577-9A9D-E2E0FE5BF3EB Q37358254-7909001E-7313-46E7-91A2-0243D86BEBE9 Q37691090-AD726F20-AC8D-4875-8626-3475E6FF3DA6 Q37968143-0858E7E7-CFA8-47C1-B75A-148D5727A03F Q38098104-5F472E7A-9E07-460A-9C9A-EA525AFBE3FA Q38110227-ACAC870B-58FC-41B6-8B9E-E64FAC5AA4CB Q38245618-86843C15-73B6-48C6-9A8A-437CDEB6DC54 Q38522457-5BEE7F6F-4246-4CBB-99FF-075419FBFC2A Q38569688-3914AE89-02D1-412F-885A-CD76726E3A6E Q38839530-EBD03BF6-7920-4C91-B179-7A672CAD25E1 Q38955830-E6F6C889-805E-4371-AF59-88481E940E84 Q39712672-4288CB0A-C8E3-44F3-8CCD-12282266BA89 Q40509594-0CA937E3-0850-4B5A-8EDA-4E2F69C3456A Q41013718-4444DDA5-6D43-45D5-A29F-ECF4048EC79D Q42021846-40D6D5FF-FECB-457B-A5CA-E0CF5198B9A9 Q42283198-9060B868-1536-4A04-AA21-46C041195791 Q42748102-DCFD9DD7-81C9-49EF-8FA6-1494E99ABBDC Q43675571-10C2D4D6-4401-4FE3-8B55-E1B9751850C4 Q44640038-D802D1B1-5C4E-4CC1-90C1-EF889122BA63 Q44996795-9CB29F0C-EBF7-4FBE-A4CA-9DBD3CBB3D7B Q46791080-640B1DFD-C515-4D53-84DF-46CEAE47F763 Q47104739-289B8B43-5E5A-41DD-AD5A-23749B82420F Q48278236-170643F9-0316-40E6-96A5-C8B4AC978D92 Q51069741-C1BACEFE-FA99-4642-832D-B1CFDACB8139 Q51546311-29647D16-D0C0-46B0-BC71-A217EDA73026

P2860

Management of rheumatoid arthritis: summary of NICE guidance.

http://www.wikidata.org/entity/Q35699212

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Management of rheumatoid arthritis: summary of NICE guidance.

@ast

Management of rheumatoid arthritis: summary of NICE guidance.

@en

type

label

Management of rheumatoid arthritis: summary of NICE guidance.

@ast

Management of rheumatoid arthritis: summary of NICE guidance.

@en

prefLabel

Management of rheumatoid arthritis: summary of NICE guidance.

@ast

Management of rheumatoid arthritis: summary of NICE guidance.

@en

P1433

Q35699212-81F42A24-8CD2-48CF-A88E-EAF3D78D5F91

P1476

Q35699212-0589A028-0EC6-4B6D-A7F6-FD2EBD1345F1

P2093

Q35699212-64D40B97-7FBE-4C5A-9B16-7BF8F33A5DD6

Q35699212-A0A21FFB-42B4-48A8-AFC9-A3E1F4B581CD

Q35699212-BB448CEC-60A9-44E1-BD08-A607B7076E9A

Q35699212-BEDB5456-C139-4C72-B3B0-F94E4943527B

Q35699212-CE43CCC8-5C18-4293-A68D-3D1E54026FB0

P2860

Q35699212-5930F0E2-8CB2-4ED0-819D-2F52308E50C3

Q35699212-BE4595F3-4B99-43F8-A325-4BC508C36306

Q35699212-DAB34495-C020-424F-9659-746A1EDCA21D

Q35699212-DB7F912D-2515-4731-B2AA-EBEF9CB26B04

P304

Q35699212-C51F8470-FF26-4EDC-8AE6-C8C56BED3D83

P31

Q35699212-59281920-F85C-4D61-A3AE-3AF9097AE77E

P356

Q35699212-972F0322-2D55-4491-9921-1AAAFDC6E4CF

P407

Q35699212-806C49BB-76E0-4E52-8227-FC2E24C9BAA0

P478

Q35699212-BCE0C6A5-6945-4B11-9787-D82A57F8A4F8

P50

Q35699212-B5258EA7-F960-4740-A2F7-03BA5FC6099B

P577

Q35699212-EA1D1089-0C80-4239-96F6-87A350DCBD00

P5875

Q35699212-E24AFC5F-FC67-48DA-8C17-85DC8BFE2647

P698

Q35699212-C456D538-A1F0-4E15-B2F4-7369CE6975BB

P932

Q35699212-B4729008-BED7-4DDC-A95F-0BAA7F548284

P356

P1433

P1476

Management of rheumatoid arthritis: summary of NICE guidance

@en

P2093

Chris Deighton

http://www.w3.org/2001/XMLSchema#string

Claire Turner

http://www.w3.org/2001/XMLSchema#string

Guideline Development Group

http://www.w3.org/2001/XMLSchema#string

Michael Rudolf

http://www.w3.org/2001/XMLSchema#string

Rachel O'Mahony

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).

British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).

P304

b702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.B702

http://www.w3.org/2001/XMLSchema#string

P407

P478

338

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan C Tosh

P577

2009-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24203803

http://www.w3.org/2001/XMLSchema#string

P698

19289413

http://www.w3.org/2001/XMLSchema#string

P932

3266846

http://www.w3.org/2001/XMLSchema#string